Astellas Pharma also released two of their structures (7YCC; 7YCE) in 2022. Amgen subsequently disclosed three co-crystal structures of G12C inhibitors developed by Araxes Pharma, AstraZeneca, and Taiho (8DNI; 8DNJ; 8DNK). The most recent company to contribute to the structural zeitgeist around KRAS was Boehringer-Ingelheim. First with the release of four structures (7U8H; 8AFB; 8AFC; 8AFD) , and most recently, with the co-crystal structures of the non-covalent pan-KRAS inhibitor BI-2865 in complex with KRAS WT, G12C, G12D, G12V and G13D (8AZV; 8AZX; 8AZY; 8AZZ; 8B00) . This was accompanied with BI-2493 in complex with KRAS(G13D) (8ONV) , and one related precursor compound (8AZR) . Most recently, AstraZeneca released two additional structures, including the CNS penetrating AZD4747 (8B6I; 8B78) . Currently, there are two inhibitors targeting KRAS(G12C), GDC-6036 32 and LY3537982 , neither with a publicly available co-crystal structure, but both are in clinical trials (Figure ). GDC-6036 (divarasib, PubChem CID: 146624881) has advanced to phase II/III clinical trials with non-small cell lung cancer (NSCLC) , and is in phase I with combination therapies , patients with colorectal cancer (CRC) and with advanced or metastatic solid tumors . The results from the phase I metastatic solid tumor trial were recently reported . LY3537982 (PubChem CID: 156472638) is currently in phase I studies with cancer patients having KRAS(G12C) mutations . In addition, its PK is being tested on healthy individuals , including the effect of itraconazole and carbamazepine with LY3537982 . The discovery of GDC-6036 was disclosed in AACR annual meeting in 2022 .